Disease progression is slower and overall survival (OS) is greater in patients with chronic myeloid leukemia (CML) who are being monitored for their response to tyrosine kinase inhibitor (TKI) therapy and show good adherence. However, few clinicians monitor response and adherence to oral TKI treatment in patients with CML. [ Read More ]
An investigational first-in-class anticancer quinolone derivative, vosaroxin, extended median overall survival (OS) when used with cytarabine (Cytosar-U) in a phase 3 clinical trial of patients with relapsed or refractory acute myeloid leukemia (AML), although the difference was not significant. [ Read More ]
Blinatumomab Immunotherapy Attacks Minimal Residual Disease in ALL, Leads to High Rates of Complete Response
San Francisco, CA—In patients with acute lymphoblastic leukemia (ALL), assessment of minimal residual disease (MRD) is increasingly used to evaluate response to treatment. An antibody that recruits the body’s T-cells to attack MRD in patients with ALL whose disease is in remission can prevent full relapse. [ Read More ]
Washington, DC—A new framework for transforming cancer care by harnessing the meaningful use criteria of the Centers for Medicare & Medicaid Services (CMS) was proposed by a team of researchers at the 2013 American Medical Informatics Association meeting. [ Read More ]
Washington, DC—Patients with cancer are often prescribed medications for the treatment of comorbid conditions, and some of those medications may have harmful drug interactions with the therapies used to treat their cancer. Computerized alert systems are now being used to inform providers or support personnel on such contraindications. [ Read More ]
A long-standing treatment standard for indolent non-Hodgkin lymphoma (NHL) has fallen victim to the chopping block, so to speak, at least in Germany.
The use of the cyclophosphamide (Cytoxan), doxorubicin (Adriamycin), vincristine (Oncovin), and prednisone (Deltasone; CHOP) regimen with or without rituximab (Rituxan; R-CHOP) has declined rapidly with the emergence of bendamustine (Treanda), which is used either alone or with rituximab.[ Read More ]
Children with acute lymphoblastic leukemia (ALL) had no drop-off in efficacy with an anthracycline-free regimen that also reduced the long-term risk of cardiotoxicity, reported Andre Baruchel, MD, PhD, Chief of Pediatric Hematology, Robert Debré University Hospital, Paris, France.
Induction therapy without daunorubicin (Cerubidine) led to a 5-year event-free survival (EFS) rate of almost 97%, slightly better than the rate observed in children who received conventional induction that included the anthracycline agent.[ Read More ]
An independent health information technology company, eviti, Inc, provides a suite of web-based decision-support services that connects and delivers value to all parties in the care process—patients receive quality care, physicians are assured payment, insurers pay for quality care only, and pharmacy benefit managers (PBMs) or specialty pharmacy improve adherence. This decision support platform is a transformative solution that reduces variability in care, improves quality, and enables realignment of provider incentives.[ Read More ]
[ Read More ]